Association of baseline advanced HIV disease and dolutegravir versus non-dolutegravir regimen status with viral load suppression among patients on antiretroviral therapy in Tanzania

Read full text Summarise with VIRAT
Authors: Hamisi Amiri Dani, Prosper Njau, Raphael Zozimus Sangeda
Cited by: 0
References: 20

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Dolutegravir (DTG)-based regimens are currently the preferred first-line therapy in many HIV programs; however, the influence of baseline advanced HIV disease (AHD) on virologic outcomes in routine national data in the DTG era remains unclear. Methods We conducted a retrospective cohort analysis using routinely collected data from Tanzania’s National AIDS, STIs, and Hepatitis Control Programme (NASHCoP) database (2017-2021). A simple random sample of 50,000 patients was drawn from the de-duplicated national dataset, yielding 49,863 patients after data processing. The analytic cohort included 4,044 patients with baseline CD4 and endpoint viral load measurements. Viral load suppression was defined as

Fields of Study & Subjects

HIV/AIDS Research and Interventions HIV/AIDS drug development and treatment HIV Research and Treatment

Publication details

Journal / source
medRxiv
Publication date
23 March 2026
Language
EN
Document type
Preprint